NCT02319408已完成不适用
A Randomized Phase II Study of Radiation Induced Immune Boost in Operable Non-small Cell Lung Cancer
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 36
- 试验地点
- 4
- 主要终点
- Cluster of differentiation (CD)8+ T cells in resected NSCLC
研究概览
简要总结
Insufficient migration and activation of tumour specific effector T cells seems to be the one important reason for inadequate host anti-tumour immune response. Ionizing radiation can induce a variety of immune responses. The goal of this randomized trial is to assess if a preoperative single fraction low dose radiation is able to improve anti-tumour immune response in operable early stage lung cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically proven clinical stage I to IIA pulmonary adenocarcinoma
- •Lung tumor is felt to be curatively resectable by the treating physicians
- •Sufficient pulmonary function for lobectomy according to current guidelines
- •The patient is free of distant metastases as confirmed by contrast-enhanced chest and upper abdomen CT-scan and by contrast-enhanced CT or MRI of the brain
- •Age over 50years at the time of consent due to federal radiation protection law
- •In female patients of childbearing potential there must be a negative pregnancy test
- •Eastern Cooperative Oncology Group performance status of 0,1, 2 or 3 at the time of randomization
- •Patients who the investigator believes can and will comply with the requirements of this protocol
- •Written informed consent according to good clinical practise and national/regional regulations
排除标准
- •The patient shows clinical signs of pneumonia
- •The patient receives immunosuppressive drugs (alkylating agents, antimetabolites, methotrexate, azathioprine, mercaptopurine, cytotoxic antibodies, ciclosporin, tacrolimus, sirolimus, interferon, mycophenolate, small biological agents)
- •The patient has been diagnosed with a potential immune mediated disease
- •Elevated blood leukocyte count or erythrocyte sedimentation rate
- •Pregnancy
- •The patient has received any cancer specific treatment, including radiotherapy, immunotherapy, hormonal therapy or chemotherapy
- •The patient is diagnosed with a concomitant malignancy and/or has a history of malignancy within the past five years or has had a malignancy that has been in complete remission for less than 5 years
- •The patient needs chronic long term oxygen therapy
- •The patient has undergone splenectomy
- •The patient is known to be HIV positive
- •The patient has an uncontrolled bleeding disorder
结局指标
主要结局
Cluster of differentiation (CD)8+ T cells in resected NSCLC
时间窗: 7 days
Frequencies of CD8+ T cells in resected NSCLC tumors determined by immunohistochemistry
次要结局
- T cell subtypes in resected NSCLC(7 days)
研究者
Dr. med. Seyer Safi
Dr. med. Seyer Safi
University Hospital Heidelberg
研究点 (4)
Loading locations...
相似试验
Unknown
1 期
Effect of Neoadjuvant Radiation on Tumor Infiltrating T-cells by Low Dose Radiation in Colorectal Liver MetastasesColorectal Liver MetastasesNCT01191632Heidelberg University40
Unknown
2 期
Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI TherapyLung AdenocarcinomaNCT02787447First People's Hospital of Hangzhou46
已完成
不适用
Hypofractionation With Simultaneous Integrated Boost for Early Breast CancerSurgeryAdjuvant RadiotherapyBreast CancerNCT04913532Capital Medical University35
招募中
不适用
A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.Her-2 Negative Adenocarcinoma of the Gastro-oesophageal Junction/Gastric AdenocarcinomaBiliary Tract CarcinomaColorectal AdenocarcinomaHepatocellular CarcinomaNCT06349044Zhejiang Cancer Hospital120
已完成
不适用
T-cell-immunity During Standard Radiotherapy in Localised Prostate CancerProstate CancerNCT01376674University Hospital Tuebingen22